We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

395 hedge funds and large institutions have $8.86B invested in Royalty Pharma in 2024 Q3 according to their latest regulatory filings, with 59 funds opening new positions, 159 increasing their positions, 123 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,323% more call options, than puts

Call options by funds: $20.8M | Put options by funds: $1.47M

51% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 39

29% more repeat investments, than reductions

Existing positions increased: 159 | Existing positions reduced: 123

29% more funds holding in top 10

Funds holding in top 10: 7 → 9 (+2)

6% more capital invested

Capital invested by funds: $8.35B → $8.86B (+$508M)

4% more funds holding

Funds holding: 378 → 395 (+17)

0.21% less ownership

Funds ownership: 70.09% → 69.88% (-0.21%)

Holders
395
Holders Change
+17
Holders Change %
+4.5%
% of All Funds
5.67%
Holding in Top 10
9
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+28.57%
% of All Funds
0.13%
New
59
Increased
159
Reduced
123
Closed
39
Calls
$20.8M
Puts
$1.47M
Net Calls
+$19.4M
Net Calls Change
+$10.1M

Top Buyers

1
Millennium Management
Millennium Management
New York
+$55.2M
2
Amundi
Amundi
France
+$45.1M
3
Deutsche Bank
Deutsche Bank
Germany
+$37.7M
4
Charles Schwab
Charles Schwab
California
+$30.6M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$26.8M

Top Sellers

1
JP Morgan Chase
JP Morgan Chase
New York
-$179M
2
UE
Unisphere Establishment
Liechtenstein
-$132M
3
Morgan Stanley
Morgan Stanley
New York
-$84.6M
4
Aberdeen Group
Aberdeen Group
United Kingdom
-$30M
5
Invesco
Invesco
Georgia
-$28.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
CCS
401
Concentric Capital Strategies
Connecticut
– -$2.66M -100,968 Closed
PI
402
PGGM Investments
Netherlands
– -$2.42M -91,855 Closed
LIP
403
Lighthouse Investment Partners
Florida
– -$1.98M -75,103 Closed
KWM
404
Kingsview Wealth Management
Oregon
– -$1.77M -67,145 Closed
Toronto Dominion Bank
405
Toronto Dominion Bank
Ontario, Canada
– -$1.15M -43,714 Closed
Walleye Capital
406
Walleye Capital
New York
– -$992K -37,635 Closed
IG
407
ING Group
Netherlands
– -$963K -36,500 Closed
Pacer Advisors
408
Pacer Advisors
Pennsylvania
– -$959K -36,353 Closed
MPM
409
MBB Public Markets
Illinois
– -$715K -27,114 Closed
PRC
410
Pearl River Capital
Michigan
– -$635K -24,062 Closed
BF
411
BOK Financial
Oklahoma
– -$483K -18,311 Closed
Rockefeller Capital Management
412
Rockefeller Capital Management
New York
– -$419K -15,873 Closed
CM
413
Capula Management
Cayman Islands
– -$408K -15,470 Closed
Truist Financial
414
Truist Financial
North Carolina
– -$356K -13,486 Closed
DTL
415
Dynamic Technology Lab
Singapore
– -$315K -11,955 Closed
MAM
416
Martingale Asset Management
Massachusetts
– -$312K -11,818 Closed
GCGDR
417
Geo Capital Gestora de Recursos
Brazil
– -$307K -11,643 Closed
AA
418
ALPS Advisors
Colorado
– -$303K -11,488 Closed
NC
419
nVerses Capital
Florida
– -$301K -11,400 Closed
FHB
420
First Hawaiian Bank
Hawaii
– -$267K -10,119 Closed
Envestnet Portfolio Solutions
421
Envestnet Portfolio Solutions
Illinois
– -$254K -9,616 Closed
Acadian Asset Management
422
Acadian Asset Management
Massachusetts
– -$250K -9,516 Closed
VI
423
Versor Investments
New York
– -$236K -8,942 Closed
William Blair & Company
424
William Blair & Company
Illinois
– -$222K -8,420 Closed
IGAM
425
iA Global Asset Management
Quebec, Canada
– -$168K -6,388 Closed
14 15 16
17
18

RPRX Hedge Fund Activity: Q3 2024 in Review

395 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q3 2024, worth a combined $8.86B — up 6.1% from $8.35B a quarter earlier.

Buyers outnumbered sellers: 59 funds opened new RPRX positions and 39 closed out — a net gain of 20 holders — while 159 added to existing stakes and 123 trimmed.

The largest buyer was Millennium Management, adding an estimated $55.2M. The largest seller was JP Morgan Chase, cutting an estimated $179M.

  • 395 institutional investors held Royalty Pharma (RPRX) as of Q3 2024, up from 378 in Q2 2024.
  • Funds reported $8.86B of Royalty Pharma stock for Q3 2024, up 6.1% quarter-over-quarter.
  • 59 funds opened new Royalty Pharma positions in Q3 2024 and 39 closed out, a net change of +20 holders.
  • The largest Royalty Pharma buyer in Q3 2024 was Millennium Management, an estimated $55.2M added.
  • The largest Royalty Pharma seller in Q3 2024 was JP Morgan Chase, an estimated $179M sold.

Based on aggregated 13F filings for Q3 2024.